L-FABP Inhibitors
L-FABP Inhibitors represent a class of chemicals that can modulate the activity of Liver Fatty Acid-Binding Protein (L-FABP) through various mechanisms. These compounds, such as BMS309403 and GW7647, exhibit their inhibitory effects by targeting closely related proteins or receptors, ultimately disrupting the functions of fatty acid transport proteins or influencing lipid metabolism. BMS309403, a selective inhibitor of Fatty Acid-Binding Protein 4 (FABP4), shares structural similarities with L-FABP and indirectly inhibits L-FABP by interfering with the functions of related fatty acid transport proteins.
Additionally, agonists of Peroxisome Proliferator-Activated Receptors (PPARs), such as TZDs and Clofibrate, indirectly inhibit L-FABP by regulating lipid metabolism and fatty acid transport, impacting pathways related to fatty acid utilization that intersect with L-FABP functions. These inhibitors showcase the intricate relationship between L-FABP and lipid-related pathways, where modulation of these pathways can lead to indirect inhibition of L-FABP activity. Furthermore, compounds like Etomoxir and Malonyl-CoA target enzymes involved in fatty acid oxidation and transport, respectively, indirectly inhibiting L-FABP by disrupting the flow of fatty acids and their interactions with L-FABP. OEA, an endogenous lipid that activates PPARα, indirectly inhibits L-FABP by modulating lipid metabolism pathways that intersect with L-FABP functions. Similarly, the inhibition of glutathione synthesis by L-Buthionine-(S,R)-sulfoximine (BSO) leads to elevated oxidative stress, indirectly inhibiting L-FABP by affecting redox-sensitive pathways that intersect with L-FABP-related functions. Collectively, L-FABP Inhibitors offer valuable insights into strategies for inhibiting L-FABP activity through their actions on various cellular pathways and processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
FABP4 Inhibitor | 300657-03-8 | sc-202606 | 5 mg | $208.00 | 2 | |
FABP4 Inhibitor (BMS309403) shares structural similarities with L-FABP. By targeting FABP4, it can indirectly affect L-FABP by disrupting the functions of closely related fatty acid transport proteins. | ||||||
GW 7647 | 265129-71-3 | sc-203068A sc-203068 sc-203068B sc-203068C | 1 mg 5 mg 10 mg 25 mg | $49.00 $170.00 $267.00 $661.00 | 6 | |
GW7647 is an agonist of peroxisome proliferator-activated receptor alpha (PPARα), which plays a role in regulating lipid metabolism. Activation of PPARα can indirectly inhibit L-FABP by modulating lipid-related pathways that intersect with L-FABP functions. | ||||||
(+)-Etomoxir sodium salt | 828934-41-4 | sc-215009 sc-215009A | 5 mg 25 mg | $151.00 $506.00 | 3 | |
Etomoxir inhibits carnitine palmitoyltransferase 1 (CPT1), a key enzyme in fatty acid oxidation. By inhibiting CPT1, Etomoxir can indirectly inhibit L-FABP by disrupting the flow of fatty acids and their interactions with L-FABP. | ||||||
L-Buthionine sulfoximine | 83730-53-4 | sc-200824 sc-200824A sc-200824B sc-200824C | 500 mg 1 g 5 g 10 g | $286.00 $442.00 $1532.00 $2975.00 | 26 | |
BSO is an inhibitor of glutathione synthesis, leading to increased oxidative stress. Elevated oxidative stress can indirectly inhibit L-FABP by affecting redox-sensitive pathways that intersect with L-FABP-related functions. | ||||||
Arachidonic Acid (20:4, n-6) | 506-32-1 | sc-200770 sc-200770A sc-200770B | 100 mg 1 g 25 g | $92.00 $240.00 $4328.00 | 9 | |
Arachidonic Acid is a precursor for various eicosanoids, including prostaglandins and leukotrienes. Modulation of arachidonic acid levels can indirectly influence L-FABP by impacting eicosanoid signaling pathways that intersect with L-FABP functions. | ||||||
Clofibrate | 637-07-0 | sc-200721 | 1 g | $33.00 | ||
Clofibrate is a PPARα agonist that indirectly inhibits L-FABP by regulating lipid metabolism and fatty acid transport. PPARα activation can affect pathways related to fatty acid utilization, intersecting with L-FABP-associated functions. | ||||||
Oleylethanolamide | 111-58-0 | sc-201400 sc-201400A | 10 mg 50 mg | $90.00 $194.00 | 1 | |
OEA is an endogenous lipid that can activate PPARα and indirectly inhibit L-FABP by modulating lipid metabolism pathways that intersect with L-FABP functions. | ||||||
Indomethacin | 53-86-1 | sc-200503 sc-200503A | 1 g 5 g | $29.00 $38.00 | 18 | |
Indomethacin is a non-steroidal anti-inflammatory drug (NSAID) that can indirectly inhibit L-FABP by influencing arachidonic acid metabolism and eicosanoid signaling pathways that intersect with L-FABP functions. | ||||||
Fenofibrate | 49562-28-9 | sc-204751 | 5 g | $41.00 | 9 | |
Fenofibrate is another PPARα agonist that indirectly inhibits L-FABP by regulating lipid metabolism and fatty acid transport, impacting pathways related to fatty acid utilization that intersect with L-FABP-associated functions. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Resveratrol activates SIRT1, a NAD+-dependent deacetylase. Activation of SIRT1 can indirectly inhibit L-FABP by modulating acetylation of proteins involved in lipid metabolism and signaling pathways that intersect with L-FABP functions. | ||||||